Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Arch Osteoporos ; 16(1): 90, 2021 06 07.
Article in English | MEDLINE | ID: mdl-34100118

ABSTRACT

INTRODUCTION: Hip fracture rates in Botswana were used to create a FRAX® model for fracture risk assessment. OBJECTIVE: This paper describes the development and characteristics of a country-specific FRAX model for Botswana. METHODS: Age-specific and sex-specific incidence of hip fracture and national mortality rates was incorporated into a FRAX model for Botswana. Ten-year fracture probabilities were compared with those from African countries having a FRAX model and African Americans from the USA. RESULTS: The probabilities of hip fracture and major osteoporotic fracture were low compared with those from South Africa (Black and Coloured) and US Blacks. Probabilities were marginally higher than for Tunisia. CONCLUSION: The creation of a FRAX model is expected to help guide decisions about the prevention and treatment of fragility fractures in Botswana.


Subject(s)
Hip Fractures , Osteoporotic Fractures , Botswana , Female , Humans , Male , Risk Assessment , Risk Factors , South Africa
2.
Arch Osteoporos ; 16(1): 24, 2021 02 07.
Article in English | MEDLINE | ID: mdl-33550503

ABSTRACT

A retrospective population-based survey in the Republic of Botswana determined the incidence of fractures at the hip over 3 years. The estimated number of such fractures nationwide for 2020 was 103 and is predicted to increase. OBJECTIVE: This article describes the epidemiology of hip fractures in the Republic of Botswana. METHODS: A retrospective patient chart review was conducted to identify from hospital registers the number of patients diagnosed with hip fracture in 2009, 2010, and 2011. Age- and sex-specific incidence of hip fracture was determined from which lifetime probabilities and future projections for hip fracture were calculated. RESULTS: The incidence of hip fracture was low and comparable to rates reported from Tunisia. The remaining lifetime risk of hip fracture at the age of 50 years in men and women was 1.4 and 1.1%, respectively. The incidence of hip fracture suggested that the estimated number of hip fractures nationwide in persons over the age of 50 years for 2020 was 103 and is predicted to increase by more than threefold to 372 in 2050. CONCLUSION: The hip fracture rates can be used for healthcare planning. Additionally, these data can be used to create a FRAX model to help guide decisions about treatment.


Subject(s)
Hip Fractures , Osteoporotic Fractures , Botswana/epidemiology , Female , Hip Fractures/epidemiology , Humans , Incidence , Male , Middle Aged , Retrospective Studies , Risk Assessment
3.
Med J Armed Forces India ; 52(2): 133-134, 1996 Apr.
Article in English | MEDLINE | ID: mdl-28769366
4.
J Trauma ; 27(10): 1173-6, 1987 Oct.
Article in English | MEDLINE | ID: mdl-3312625

ABSTRACT

The effect of 'low-dose' corticosteroids (9 mg/kg methylprednisolone), given after skeletal trauma, on the incidence of the fat embolism syndrome and isolated arterial hypoxemia was studied in 42 controls and 40 steroid-treated subjects. Fat embolism occurred in ten controls (23.8%) and one steroid-treated subject (2.5%) (p = 0.01). A further 44 subjects developed isolated hypoxemia. This was severe (PaO2 less than 50 mm Hg) in seven of 32 controls (21.9%) and one of 39 steroid-treated subjects (2.6%) (p = 0.01). The overall incidence of hypoxemia was 67.1%, affecting 33 controls (78.6%) and 22 steroid-treated patients (55%) (p less than 0.05). The degree of hypoxemia was severe (PaO2 less than 50 mm Hg) in 12 controls (28.6%) and two (5%) of the steroid-treated subjects (p = 0.005). No control subject died or required mechanical ventilation. One steroid-treated subject without fat embolism died of a fulminant infection. Although methylprednisolone in a relatively low dose provides protection against fat embolism and pulmonary dysfunction after skeletal trauma, the safety of this therapy requires further evaluation.


Subject(s)
Embolism, Fat/prevention & control , Femoral Fractures/complications , Fibula/injuries , Fractures, Bone/complications , Methylprednisolone/administration & dosage , Tibial Fractures/complications , Adult , Clinical Trials as Topic , Embolism, Fat/etiology , Female , Humans , Hypoxia/prevention & control , Male , Methylprednisolone/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...